Navigation Links
Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
Date:3/19/2013

Division Chair, University of Wisconsin, "The data presented at AAN from the development program for USL261 support the safety profile and favorable pharmacokinetics/pharmacodynamics of USL261 in healthy volunteers.  These findings support the further development of USL261 for seizure rescue in patients with intermittent bouts of increased seizure activity, a population for which few treatment options are currently available."

USL261 (Intranasal Midazolam) Data  

USL261 data presented at AAN 2013 examined the pharmacokinetics, pharmacodynamics, safety, and tolerability of USL261 in healthy volunteers.  In this study, increasing USL261 doses corresponded with an apparent linear increase in midazolam exposure, with all doses demonstrating rapid time to maximal plasma concentration (10 – 15 min).  Researchers concluded that USL261 dosed up to 7.5 mg was generally well tolerated and did not result in excessive or prolonged sedation or psychomotor impairment.  Further, when compared with an equivalent dose of injectable midazolam delivered intranasally, USL261 demonstrated improved midazolam bioavailability with similar pharmacodynamic effects and safety/tolerability profiles.  

Abstracts of the poster presentations can be found online at: http://www.aan.com 

  • Safety and Pharmacodynamics of USL261, a Novel Formulation of Midazolam Optimized for Intranasal Administration
    P02.211. Session P02:  Epilepsy:  Novel Therapeutics and Basic Science
  • Pharmacokinetics of USL261, a Novel Formulation of Intranasal Midazolam
    P02.212. Session P02:  Epilepsy:  Novel Therapeutics and Basic Science

About Epilepsy

Epilepsy is a medical condition that causes seizures affecting a variety of cognitive and physical functions.  More than two million
'/>"/>

SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters
2. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
3. Assemblyman Levine Presents Resolution Recognizing Rare Disease Day at Capitol
4. Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading Dentist on Dental Pulp Stem Cells
5. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
6. Bluestar Silicones Presents Soft Silicone Advantages At Medical Design And Manufacturing (MD&M) West Show
7. Oracle’s Value Chain Summit San Francisco: Track Sponsor NexInfo presents more industry specific solutions
8. Fertility Associates of Memphis, World-Renowned Expert in Infertility, Presents Findings to European Conference
9. BCA Represents Independent Blood Centers at Phacilitate Cell & Gene Therapy Forum
10. HealthEconomics.Com Presents Top News Stories in Pharma Reimbursement and Pricing from this Week's Newsletter
11. NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Custom Learning Designs, Inc.(CLD) ... solution using Tin Can API combined with its ... is a leading developer of training content and ... worldwide. , Tin Can API is a ... and trainers more accurately measure the Return on ...
(Date:5/21/2013)... , May 21, 2013 ... Dialysis and Transplant Association) is the biggest congress in ... replacement therapy. Nearly 10,000 participants are in ... the latest research findings. New pioneering studies have been ... "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA ...
(Date:5/21/2013)... According to a new market ... "Biochip Products and Services Market (Microarrays, Reagents, Drug Discovery, ... Share, Growth, Trends and Forecast, 2012 - 2018," the market was valued ... to grow at a CAGR of 10.1% from 2012 ... 4.7 billion in 2018. Browse the full ...
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
Breaking Biology Technology:CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... plays a key role in determining risk for colorectal ... the United States. Several common genetic markers have ... finding the biological events that lead to cancer can ... online in Genome Research (www.genome.org), scientists have ...
... chemical analysts are expected to track down even ... work, nano researchers have developed minute strings that ... onto one of the strings, then it becomes ... recently, however, such "nano-electromechanical systems", or NEMS, have ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ), a ... novel medicines in the areas of hepatitis C and ... the first quarter ended March 31, 2009. "We have ... a study in HCV patients that demonstrated potent antiviral ...
Cached Biology Technology:Beyond associations: Colorectal cancer culprit found 2Scientists moving closer to 'artificial noses' 2Scientists moving closer to 'artificial noses' 3Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 2Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 3Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 4Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 5Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 6Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 7Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 8Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 9Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights 10
(Date:5/21/2013)... scientists have developed many devices that can reopen clogged ... effective, each of these treatments has drawbacks, including the ... MIT analyzes the potential usefulness of a new treatment ... stents, but may pose fewer risks. With this new ... only a brief period, during which it releases a ...
(Date:5/21/2013)... ANDOVER, Mass. , May 21, 2013 ... that CX50 xMATRIX, the world,s first portable ultrasound with ... Intracardiac Echo (ICE) capability. The CX50 xMATRIX with available ... Paris at the EuroPCR, official ... (EAPCI), May 21-24. Since its launch in ...
(Date:5/20/2013)... University of Minnesota Medical School researchers from the ... the University,s Brain Tumor Program, have developed a new ... that allow them to discover new genes and gene ... was published this week in the journal Nature ... researchers in the lab of David Largaespada, Ph.D., professor ...
Breaking Biology News(10 mins):Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2U of M researchers develop model for better testing, targeting of MPNST 2
... Transposons are the Clark Kents of a genome. ... activity, these free-floating bits of genetic material have for ... of plants and animals, dramatically increasing a genome,s size. ... DNA was passive "junk" and knew little about it. ...
... available in French . , Montreal, ... and foster weight gain during puberty, according to a ... Endocrinology & Metabolism . Even in sun-drenched California, where ... the University of Southern California conducted their study, vitamin ...
... 10, 2008) A study published in the current ... suggests that mature adipocytes - fat cells - could ... central nervous system disorders. , According to the study,s ... Medical Science, St. Mariana University School of Medicine, Kawasaki, ...
Cached Biology News:New research shows how gene function drives natural selection in important class of genetic elements 2New research shows how gene function drives natural selection in important class of genetic elements 3Lack of vitamin D causes weight gain and stunts growth in girls 2Transplanted fat cells restore function after spinal cord injury 2
GlutaMAX-I Supplement...
... Dissociation Buffers are membrane-filtered isotonic and ... agents and cell-conditioning agents in either ... solution or Ca2+- and Mg2+-free ... mammalian cells from support substrates and ...
Goat polyclonal to PINX1 ( Abpromise for all tested applications). entrezGeneID: 54984 SwissProtID: Q548A5...
...
Biology Products: